aDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA bDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA ...

Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis, psoriasis, ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Intas Pharmaceuticals has received approval from the Subject Expert Committee (SEC), functioning under the Central Drugs ...

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...

China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma: Hong Kong, Shanghai Friday, June 6, 2025, 09:00 Hr ...

Department of Chemistry, University of California, Berkeley, California 94720, United States Department of Chemistry, University of California, Berkeley, California 94720, United States Department of ...